Regeneron Pharmaceuticals (REGN) Accumulated Expenses (2010 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Accumulated Expenses of $3.0 billion for Q2 2026, up 20.53% year-over-year from $2.5 billion in Q2 2025, and up 8.89% quarter-over-quarter from $2.7 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Accumulated Expenses (2010 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $3.0 billion for Q2 2026.
- In Q2 2026, Accumulated Expenses rose 20.53% year-over-year to $3.0 billion; the TTM figure through Jun 2026 stood at $3.0 billion (up 20.53% YoY), while the FY2025 annual figure was $2.9 billion, up 13.82% from the prior year.
- Accumulated Expenses for Q2 2026 stood at $3.0 billion, up from $2.7 billion in the prior quarter.
- The five-year high for Accumulated Expenses was $3.0 billion in Q3 2025, with the low at $1.8 billion in Q3 2022.
- The 5-year median for Accumulated Expenses is $2.4 billion (2024), against an average of $2.4 billion.
- The sharpest annual moves came in 2022 and 2023: Accumulated Expenses retreated 12.84% in 2022, then soared 47.22% in 2023.
- Regeneron Pharmaceuticals' Accumulated Expenses stood at $2.1 billion in 2022, then increased by 13.68% to $2.4 billion in 2023, then advanced by 7.18% to $2.5 billion in 2024, then gained by 13.82% to $2.9 billion in 2025, then grew by 3.13% to $3.0 billion in 2026.
- Business Quant data shows REGN's Accumulated Expenses at $3.0 billion in Q2 2026, $2.7 billion in Q1 2026, and $2.9 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.97 Bn |
| Mar 31, 2026 | 2.72 Bn |
| Dec 31, 2025 | 2.88 Bn |
| Sep 30, 2025 | 2.98 Bn |
| Jun 30, 2025 | 2.46 Bn |
| Mar 31, 2025 | 2.24 Bn |
| Dec 31, 2024 | 2.53 Bn |
| Sep 30, 2024 | 2.54 Bn |
| Jun 30, 2024 | 2.36 Bn |
| Mar 31, 2024 | 2.39 Bn |
| Dec 31, 2023 | 2.36 Bn |
| Sep 30, 2023 | 2.64 Bn |
| Jun 30, 2023 | 2.18 Bn |
| Mar 31, 2023 | 2.07 Bn |
| Dec 31, 2022 | 2.07 Bn |
| Sep 30, 2022 | 1.80 Bn |
| Jun 30, 2022 | 1.93 Bn |
| Mar 31, 2022 | 2.05 Bn |
| Dec 31, 2021 | 2.21 Bn |
| Sep 30, 2021 | 2.06 Bn |